---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-021758"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:36:06.530754+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Indaptus reports Q3 loss per share $2.98, cash $5.8M; pauses enrollment pending Decoy20 combo efficacy

## Summary
- Q3 2025 loss per share $2.98 vs $9.04 YoY; cash $5.8M at Sept 30, expected to fund into Q1 2026.
- Completed Safety Lead-In cohort, dosing 6 participants with Decoy20 + tislelizumab; 3 stable disease, 2 remain on study.
- Enrollment paused pending additional efficacy evaluation and assessment of next development options.
- Raised $2.3M via ATM in September 2025; converted $5.7M promissory notes into stock/warrants in July.

## SEC filing metadata
- accession: 0001493152-25-021758
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315225021758/0001493152-25-021758-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315225021758/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-021758
- JSON: https://secwatch.observer/filing/0001493152-25-021758.json
- Plain text: https://secwatch.observer/filing/0001493152-25-021758.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.